Citations

Clear

16280 citation(s) found for "Yu, David".

RNAi screening of the kinome with cytarabine in leukemias
Tibes, Raoul , Bogenberger, James M. , Chaudhuri, Leena, Hagelstrom, R. Tanner, Chow, Donald, Buechel, Megan, Gonzales, Irma M. , Demuth, Tim, Slack, James L., Braggio, Esteban , Yin, Hongwei , Arora, Shilpi , Azorsa, David O. , Mesa, Ruben A. , Braggio, Esteban , Bogenberger, James

Mayo Clinic

Blood | January 21, 2012 | Volume: 119 | Issue: 12 | Pages: 2863-2872

10.1182/blood-2011-07-367557 | PMID 22267604 Get It

AbstractTo identify rational therapeutic combinations with cytarabine (Ara-C), we developed a high-throughput, small-interference RNA (siRNA) platform for myeloid leukemia cells. Of 572 kinases individually silenced in combination with Ara-C, silencing of 10 (1.7%) and 8 (1.4%) kinases strongly increased Ara-C activity in TF-1 and THP-1 cells, respectively. The strongest molecular concepts emerged around kinases involved in cell-cycle checkpoints and DNA-damage repair. In confirmatory siRNA assays, inhibition of WEE1 resulted in more potent and universal sensitization across myeloid cell lines than siRNA inhibition of PKMYT1, CHEK1, or ATR. Treatment of 8 acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML) cell lines with commercial and the first-in-class clinical WEE1 kinase inhibitor MK1775 confirmed sensitization to Ara-C up to 97-fold. Ex vivo, adding MK1775 substantially reduced viability in 13 of 14 AML, CML, and myelodysplastic syndrome patient samples compared with Ara-C alone. Maximum sensitization occurred at lower to moderate concentrations of both drugs. Induction of apoptosis was increased using a combination of Ara-C and MK1775 compared with using either drug alone. WEE1 is expressed in primary AML, ALL, and CML specimens. Data from this first siRNA-kinome sensitizer screen suggests that inhibiting WEE1 in combination with Ara-C is a rational combination for the treatment of myeloid and lymphoid leukemias.
Noise Reduction to Decrease Radiation Dose and Improve Conspicuity of Hepatic Lesions at Contrast-Enhanced 80-kV Hepatic CT Using Projection Space Denoising
Ehman, Eric C. , Guimarães, Luís , Fidler, Jeff L. , Takahashi, Naoki , Ramírez-Giraldo, Juan Carlos , Yu, Lifeng , Huprich, James E., Holmes, David R. , Harmsen, William S. , Fidler, Jeff L. , Yu, Lifeng , Manduca, Armando , McCollough, Cynthia H. , Fletcher, Joel G. , Takahashi, Naoki

Mayo Clinic

American Journal of Roentgenology | January 19, 2012 | Volume: 198 | Issue: 2 | Pages: 405-411

10.2214/ajr.11.6987 | PMID 22268185 Get It

Partial Pathologic Response and Nodal Status as Most Significant Prognostic Factors for Advanced Rectal Cancer Treated With Preoperative Chemoradiotherapy
Huebner, Marianne , Wolff, Bruce G., Smyrk, Thomas C. , Aakre, Jeremiah A. , Larson, David W.

Mayo Clinic

World Journal of Surgery | January 19, 2012 | Volume: 36 | Issue: 3 | Pages: 675-683

10.1007/s00268-011-1409-8 | PMID 22270980 Get It

AbstractBackgroundThis study evaluated the impact of tumor regression grading (TRG) and other pathologic variates in a cohort of rectal carcinoma patients treated with neoadjuvant chemoradiotherapy (CRT). The value of a grading less than pCR for predicting survival is unknown. Tumor budding has not been systematically studied in rectal cancer after neoadjuvant therapy.MethodsPathologic risk factors for survival were evaluated on surgical specimens of 237 patients with stages I, II, and III rectal cancer treated between 1996 and 2006. All patients underwent preoperative CRT followed by surgical resection 6–8 weeks later. TRG, tumor grade, budding, venous invasion, radial margin, and nodal status were evaluated. The prognostic value of TRG categories was calculated with Cox regression models and validated with resampling methods.ResultsTRG of <25% occurred in 61 (25.7%) and a complete response in 39 (16.4%) of the resected specimens. TRG of <25% was shown to be a statistically significant predictor for cancer‐specific survival (CSS) and recurrence‐free survival (RFS) compared to TRG ≥25% (P = 0.013). Tumor budding was present in 24 (10.1%) of the patients and was negatively associated with CSS (P = 0.013). Lymph node involvement was observed in 83 (35.0%) patients. TRG and nodal status (P < 0.001) were the most significant predictors associated with outcome.ConclusionPartial pathologic response ≥25% was a superior predictor compared to pCR for improved survival after preoperative CRT. CSS and RFS were adversely affected by the presence of lymph node metastases.
The endothelial protein C receptor (PROCR) Ser219Gly variant and risk of common thrombotic disorders: a HuGE review and meta-analysis of evidence from observational studies
Dennis, Jessica , Johnson, Candice Y. , Adediran, Adeniyi Samuel, Heit, John A. , Morange, Pierre‐Emmanuel , Trégouët, David‐Alexandre , Gagnon, France, Andrade, Mariza de

Mayo Clinic

Blood | January 18, 2012 | Volume: 119 | Issue: 10 | Pages: 2392-2400

10.1182/blood-2011-10-383448 | PMID 22251481 Get It

AbstractThe endothelial protein C receptor (EPCR) limits thrombus formation by enhancing activation of the protein C anticoagulant pathway, and therefore may play a role in the etiology of thrombotic disorders. The rs867186 single-nucleotide polymorphism in the PROCR gene (g.6936A > G, c.4600A > G), resulting in a serine-to-glycine substitution at codon 219, has been associated with reduced activation of the protein C pathway, although its association with thrombosis risk remains unclear. The present study is a highly comprehensive systematic review and meta-analysis, including unpublished genome-wide association study results, conducted to evaluate the evidence for an association between rs867186 and 2 common thrombotic outcomes, venous thromboembolism (VTE) and myocardial infarction (MI), which are hypothesized to share some etiologic pathways. MEDLINE, EMBASE, and HuGE Navigator were searched through July 2011 to identify relevant epidemiologic studies, and data were summarized using random-effects meta-analysis. Twelve candidate genes and 13 genome-wide association studies were analyzed (11 VTE and 14 MI, including 37 415 cases and 84 406 noncases). Under the additive genetic model, the odds of VTE increased by a factor of 1.22 (95% confidence interval, 1.11-1.33, P < .001) for every additional copy of the G allele. No evidence for association with MI was observed.
Reliability of the dial test using a handheld inclinometer
Levy, Bruce A. , Shah, Jay P. , Hollman, John H. , Dahm, Diane L., Krause, David A. , Stuart, Michael J. , Hollman, John

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | January 16, 2012 | Volume: 21 | Issue: 5 | Pages: 1011-1016

10.1007/s00167-011-1873-6 | PMID 22246546 Get It

AbstractPurposeThe primary purpose of this study was to investigate the intra‐tester and inter‐tester reliability of the dial test using a handheld digital inclinometer. Additionally, we examined the responsiveness of the test, and side‐to‐side differences for meaningful comparison.Materials/methodsTwenty‐four healthy subjects (22.5 ± 2.8 years) participated in the study. The dial test was performed on both knees at 30° and 90° of knee flexion with the subject supine. While maintaining a neutral position of the ankle, an inclinometer was positioned parallel to the medial border of the foot to quantify external rotation of the tibia. Two examiners performed the dial test in a blinded manner. The minimal detectable change across repeated measures and side‐to‐side difference was calculated.ResultsIntra‐tester reliability for examiner 1 (E1) was 0.83 at 30° knee flexion and 0.89 at 90° knee flexion. Reliability values for examiner 2 (E2) were 0.86 at 30° and 0.87 at 90° knee flexion. Inter‐tester reliability was 0.74 at 30° and 0.83 at 90°. The minimal detectable change (MDC) for E1 at 30° was ±9.4° and ±7.4° at 90°. For E2, the MDC value was ±9.1° at 30° and ±8.3° at 90°. Ninety‐five percent limits of agreement for side‐to‐side difference was 16.1° and 11.3° ° for E1 at 30° and 90° and for E2 13.9° at 30° and 14.1° at 90°.ConclusionsThis instrumented dial test using a handheld digital inclinometer to measure external rotation can be performed with acceptable reliability in the clinical setting. A difference of 10° between two measurements on the same knee suggests that a meaningful change has occurred. For right to left comparison, differences greater than 15° suggest clinical significance.Level of evidenceIII.
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
Kumar, Shaji , Fonseca, Rafaël , Ketterling, Rhett P. , Dispenzieri, Angela , Lacy, Martha Q. , Hayman, Suzanne R. , Dingli, David , Knudson, Ryan A., Greenberg, Alexandra J. , Russell, Stephen J. , Zeldenrust, Steven R., Lust, John A., Kyle, Robert A. , Bergsagel, Leif, Rajkumar, S. Vincent , Bergsagel, P. Leif , Gertz, Morie A. , Buadi, Francis K. , Bergsagel, P. Leif , Rajkumar, S Vincent , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Ketterling, Rhett P , Fonseca, Rafael

Mayo Clinic

Blood | January 11, 2012 | Volume: 119 | Issue: 9 | Pages: 2100-2105

10.1182/blood-2011-11-390658 | PMID 22234687 Get It

Abstract Routine incorporation of FISH into multiple myeloma (MM) diagnostic testing has led to a better appreciation of the heterogeneity of genetic abnormalities associated with this disease. We studied a group of 484 patients with newly diagnosed symptomatic MM to better understand the prevalence of the various abnormalities and the prognostic significance of the overlapping abnormalities. A translocation involving the IgH locus and 1 of the 5 recurrent partner chromosomes was seen in 161 (33%) patients, and 275 (57%) had trisomy of at least 1 odd-numbered chromosome. High-risk FISH, defined as the presence of t(4;14), t(14;16), t(14;20), or loss of P53, was seen in 115 (24%) patients; the median overall survival for this group was 3.9 years, compared with “not reached” for standard-risk patients (P < .001). Among the patients with high-risk FISH, 49 patients who also had at least 1 trisomy had a median overall survival that was not reached, compared with 3 years for high-risk patients without a concurrent trisomy (P = .01). Based on the current findings, we conclude that the presence of trisomies in patients with t(4;14), t(14;16), t(14;20), or p53 deletion abnormalities in MM ameliorates the usual adverse impact associated with these prognostic markers.
ISHNE/EHRA expert consensus on remote monitoring of cardiovascular implantable electronic devices (CIEDs)
Dubner, Sérgio , Steinberg, Jonathan S. , Stone, Peter H. , Brugada, Josép , Piotrowicz, Ryszard , Hayes, David L. , Kirchhof, Paulus , Zaręba, Wojciech , Schuger, Claudio , Aktaş, Mehmet K. , Chudzik, Michał , Israel, Carsten, Padeletti, Luigi, (Italy), Michele Brignole, Brignole, Michele , Auricchio, Angelo , Vardas, Panos , Breithardt, Günter , Mittal, Suneet , Varma, Niraj , Kirchhof, Paulus , Zareba, Wojciech

Mayo Clinic

Europace | January 10, 2012 | Volume: 14 | Issue: 2 | Pages: 278-293

10.1093/europace/eur303 | PMID 22232544 Get It

Abstract We are in the midst of a rapidly evolving era of technology-assisted medicine. The field of telemedicine provides the opportunity for highly individualized medical management in a way that has never been possible before. Evolving medical technologies using cardiac implantable devices (CIEDs) with capabilities for remote monitoring permit evaluation of multiple parameters of cardiovascular physiology and risk, including cardiac rhythm, device function, blood pressure values, the presence of myocardial ischaemia, and the degree of compensation of congestive heart failure. Cardiac risk, device status, and response to therapies can now be assessed with these electronic systems of detection and reporting. This document reflects the extensive experience from investigators and innovators around the world who are shaping the evolution of this rapidly expanding field, focusing in particular on implantable pacemakers (IPGs), implantable cardioverter-defibrillators (ICDs), devices for cardiac resynchronization therapy (CRT) (both, with and without defibrillation properties), loop recorders, and haemodynamic monitoring devices. This document covers the basic methodologies, guidelines for their use, experience with existing applications, and the legal and reimbursement aspects associated with their use. To adequately cover this important emerging topic, the International Society for Holter and Noninvasive Electrocardiology (ISHNE) and the European Heart Rhythm Association (EHRA) combined their expertise in this field. We hope that the development of this field can contribute to improve care of our cardiovascular patients.
Patency of the ophthalmic artery after flow diversion treatment of paraclinoid aneurysms
Puffer, Ross C. , Kallmes, David F. , Cloft, Harry J. , Lanzino, Giuseppe

Mayo Clinic

Journal of Neurosurgery | January 6, 2012 | Volume: 116 | Issue: 4 | Pages: 892-896

10.3171/2011.11.jns111612 | PMID 22224787 Get It

Object In this study the authors determined the patency rate of the ophthalmic artery (OphA) after placement of 1 or more flow diversion devices across the arterial inlet for treatment of proximal internal carotid artery (ICA) aneurysms, and correlated possible risk factors for OphA occlusion. Methods Nineteen consecutive patients were identified (mean age 53.9 years, range 23–74 years, all female) who were treated for 20 ICA aneurysms. In all patients a Pipeline Embolization Device (PED) was placed across the ostium of the OphA while treating the target aneurysm. Flow through the OphA after PED placement was determined by immediate angiography as well as follow-up angiograms (mean 8.7 months), compared with the baseline study. Potential risk factors for OphA occlusion, including age, immediate angiographic flow through the ophthalmic branch, status of flow within the aneurysm after placement of PEDs, whether the ophthalmic branch originated from the aneurysm dome, and number of PEDs placed across the ophthalmic branch inlet were correlated with patency rate. Results Patients were treated with 1–3 PEDs (3 aneurysms treated with placement of 1 PED, 12 with 2 PEDs, and 5 with 3 PEDs). In 17 (85%) of 20 treated aneurysms, no changes in the OphA flow were noted immediately after placement of the device. Two (10%) of 20 patients had delayed antegrade filling immediately following PED placement and 1 patient (5%) had retrograde flow from collaterals to the OphA immediately after placement of the device. One patient (5%) experienced delayed asymptomatic ICA occlusion; this patient was excluded from analysis at follow-up. At follow-up the OphA remained patent with normal antegrade flow in 13 (68%) of 19 patients, patent but with slow antegrade flow in 2 patients (11%), and was occluded in 4 patients (21%). No visual changes or clinical symptoms developed in patients with OphA flow compromise. The mean number of PEDs in the patients with occluded OphAs or change in flow at angiographic follow-up was 2.4 (SEM 0.2) compared with 1.9 (SEM 0.18) in the patients with no change in OphA flow (p = 0.09). There was no significant difference between the patients with occluded OphAs compared with nonoccluded branches based on patient age, immediate angiographic flow through the ophthalmic branch, status of flow through the aneurysm after placement of PEDs, whether the ophthalmic branch originated from the aneurysm dome, or number of PEDs placed across the ophthalmic branch inlet. Conclusions Approximately one-quarter of OphAs will undergo proximal thrombosis when covered with flow diversion devices. Even though these events were well-tolerated clinically, our findings suggest that coverage of branch arteries that have adequate collateral circulation may lead to spontaneous occlusion of those branches.
Multisite Reproducibility of the Broth Microdilution Method for Susceptibility Testing of Nocardia Species
Conville, Patricia S., Brown‐Elliott, Barbara A. , Wallace, Richard J. , Witebsky, Frank G., Koziol, Deloris E., Hall, Geraldine S., Killian, S. B., Knapp, Cindy C., Warshauer, David M., Van, Tam T., Wengenack, Nancy L. , Deml, Sharon M., Woods, Gail L.

Mayo Clinic

Journal of Clinical Microbiology | January 6, 2012 | Volume: 50 | Issue: 4 | Pages: 1270-1280

10.1128/jcm.00994-11 | PMID 22219309 Get It

ABSTRACT Antimicrobial susceptibility testing (AST) of clinical isolates of Nocardia is recommended to detect resistance to commonly used antimicrobial agents; such testing is complicated by difficulties in inoculum preparation and test interpretation. In this study, six laboratories performed repetitive broth microdilution testing on single strains of Nocardia brasiliensis , Nocardia cyriacigeorgica , Nocardia farcinica , Nocardia nova , and Nocardia wallacei . For each isolate, a total of 30 microdilution panels from three different lots were tested at most sites. The goal of the study was to determine the inter- and intralaboratory reproducibility of susceptibility testing of this group of isolates. Acceptable agreement (>90% agreement at ±1 dilution of the MIC mode) was found for amikacin, ciprofloxacin, clarithromycin, and moxifloxacin. After eliminating MIC values from single laboratories whose results showed the greatest deviation from those of the remaining laboratories, acceptable agreement was also found for amoxicillin-clavulanic acid, linezolid, minocycline, and tobramycin. Results showed unsatisfactory reproducibility of broth microdilution testing of ceftriaxone with N. cyriacigeorgica and N. wallacei , tigecycline with N. brasiliensis and N. cyriacigeorgica , and sulfonamides with N. farcinica and N. wallacei. N. nova ATCC BAA-2227 is proposed as a quality control organism for AST of Nocardia sp., and the use of a disk diffusion test for sulfisoxazole is proposed as a check of the adequacy of the inoculum and to confirm sulfonamide MIC results.
Incremental Value of Biochemical and Echocardiographic Measures in Prediction of Ischemic Stroke
Karas, Maria , Devereux, Richard B., Wiebers, David O. , Whisnant, Jack P., Lee, Elisa T. , Howard, Barbara V. , Roman, Mary J. , Umans, Jason G. , Best, Lyle G. , Kizer, Jorge R. , Karas, Maria G

Mayo Clinic

Stroke | December 30, 2011 | Volume: 43 | Issue: 3 | Pages: 720-726

10.1161/strokeaha.111.631168 | PMID 22207511 Get It

Background and Purpose— American Indians have high rates of stroke. Improved risk stratification could enhance prevention, but the ability of biochemical and echocardiographic markers of preclinical disease to improve stroke prediction is not well-defined. Methods— We evaluated such markers as predictors of ischemic stroke in a community-based cohort of American Indians without prevalent cardiovascular or renal disease. Laboratory markers included C-reactive protein, fibrinogen, urine albumin-to-creatinine ratio, and glycohemoglobin (HbA1c), whereas echocardiographic parameters comprised left atrial diameter, left ventricular mass, mitral annular calcification, and the ratio of early to late mitral diastolic velocities. Predictive performance was judged by indices of discrimination, reclassification, and calibration. Results— After adjustment for standard risk factors, only HbA1c, albuminuria, and left atrial diameter were significantly associated with first ischemic stroke. Addition of HbA1c, although not urine albumin-to-creatinine ratio, to a basic clinical model significantly improved the C-statistic (0.714 versus 0.695; P =0.044), whereas left atrial diameter modestly enhanced integrated discrimination improvement (0.90%; P =0.004), but not the C-statistic (0.701; P =0.528). When combined with HbA1c, left atrial diameter further increased integrated discrimination improvement (1.81%; P <0.001) but not the C-statistic (0.716). No marker achieved significant net reclassification improvement. Conclusions— In this cohort at high cardiometabolic risk, HbA1c emerged as the foremost predictor of ischemic stroke when added to traditional risk factors, affording substantially improved discrimination, with a more modest contribution for left atrial diameter. These findings bolster the role of HbA1c in cardiovascular risk assessment among persons with glycometabolic disorders and provide impetus for further study of the incremental value of echocardiography in high-risk populations.